FDA Approves Apalutamide for Nonmetastatic, Castration-Resistant Prostate Cancer

February 14, 2018 – The U.S. Food and Drug Administration (FDA) today approved apalutamide for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy. This is the first FDA-approved treatment for nonmetastatic, castration-resistant prostate cancer. “This approval is the first to use the endpoint of metastasis-free survival, measuring the length of time that tumors did not spread to other parts of the … (leggi tutto)